OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Srour on Orca-Q Transplantation in Hematologic Malignancies

February 18th 2023

Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.

Dr. Aggarwal on Characteristics Associated With PSA PFS from the PRESTO Trial in Prostate Cancer

February 17th 2023

Rahul Aggarwal, MD, discusses the association between baseline characteristics and prostate-specific antigen progression-free survival in patients with high-risk biochemically relapsed prostate cancer from the phase 3 PRESTO trial.

Dr. Agarwal on the Efficacy of Talazoparib Plus Enzalutamide in First-line mCRPC

February 17th 2023

Neeraj Agarwal, MD, discusses the efficacy of talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.

Dr. Frank on CD22 CAR T-cell Therapy in Relapsed LBCL

February 17th 2023

Matthew Frank, MD, PhD, discusses findings from a single-institution phase 1 trial investigating autologous CAR T cells targeting CD22 in adults with large B-cell lymphoma, including those who relapse after or are refractory to CD19-directed CAR T-cell therapy.

Dr. Galsky on Updated Findings From the CheckMate-274 Trial in Urothelial Cancer

February 17th 2023

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.

Dr. Necchi on Key Results From Cohort B of the KEYNOTE-057 Trial in MIBC

February 17th 2023

Andrea Necchi, MD, discusses updated analysis of cohort B in the phase 2 KEYNOTE-057 trial in non-muscle invasive bladder cancer.

Dr. Hadaschik on Treatment After Apalutamide Progression in SPARTAN Trial

February 16th 2023

Boris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.

Dr. Narkhede on Siltuximab for CRS and ICANS in Hematologic Malignancies

February 16th 2023

Mayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.

Dr. Tombal on the OS Benefit of Darolutamide Plus ADT/Docetaxel in mHSPC

February 16th 2023

Bertrand Tombal, MD, PhD, discusses the overall survival benefit associated with androgen-deprivation therapy plus darolutamide in metastatic hormone-sensitive prostate cancer.

Dr. Haddad on the Effect of Anastrozole on Endocrine Suppression in ER+/HER2- Breast Cancer

February 16th 2023

Tufia C. Haddad, MD, discusses key results from a prospective trial on adjuvant anastrozole in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Goel on the Evolution of Precision and Personalized Medicine in Cancer Care

February 16th 2023

Sanjay Goel, MD, MS, discusses the evolution of precision and personalized medicine in cancer care.

Dr. Sidana on CAR T-cell Therapy in R/R Multiple Myeloma With Renal Impairment

February 16th 2023

Surbhi Sidana, MD, discusses the feasibility of administering idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma with renal impairment.

Dr. Shah on LV20.19 CAR T-cell Therapy in R/R MCL

February 16th 2023

Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Dr. Kuykendall on the Investigation of Navitoclax Plus Ruxolitinib in Myelofibrosis

February 15th 2023

Andrew Kuykendall, MD, discusses the investigation of navitoclax plus ruxolitinib in myelofibrosis.

Dr. Dreyling on Key Safety Data from the TRIANGLE Trial in MCL

February 15th 2023

Martin Dreyling, MD, discusses the key safety data from the phase 3 TRIANGLE trial in younger patients with mantle cell lymphoma.

Dr. Costa on the Implications of the KEYNOTE-522 Trial in TNBC

February 15th 2023

Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.

Dr. Choudhury on The Need for Biomarkers to Predict Benefit With PARP Inhibitors in mCRPC

February 14th 2023

Atish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.

Dr. Mukherjee on the Role of Disease Biology in the Treatment of MCL

February 14th 2023

Akash Mukherjee, MD, discusses the importance of understanding disease biology when attempting to individualize treatment approaches in mantle cell lymphoma.

Dr. Rini on the Current Standard of Care in R/R RCC

February 14th 2023

Brian I. Rini, MD, FASCO, discusses the current treatment landscape for patients with relapsed/refractory renal cell carcinoma.

Dr. Berg on Key Ongoing Trials in Metastatic Urothelial Carcinoma

February 14th 2023

Stephanie A. Berg, DO, discusses key ongoing trials in metastatic urothelial carcinoma.